ResMed Inc (BSP:R1MD34)
R$ 368.7 0.14 (0.04%) Market Cap: 216.49 Bil Enterprise Value: 218.91 Bil PE Ratio: 32.69 PB Ratio: 6.97 GF Score: 87/100

Resmed Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 06:50PM GMT
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst

Pleasure today to be joined by David Pendarvis, SVP, from ResMed. So thank you for your time today, David.

David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary

Thanks for having us, Sean.

Questions & Answers

Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst

Welcome. Maybe start by talking about the company's 2025 strategy and educate us what that means and where you're heading?

David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary

Sure. So ResMed is on a long-term journey, and we've recently solidified in on our 2025 strategy, which is trying to look at least the next 5 years out, but I think the thing I would highlight for ResMed is if you believe ResMed is on the right track and that it's -- in order to believe it's a good investment, you really have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot